Current approaches of tumor immunotherapy

Krisztina Buzás, A. Kiss, C. Vízler

Research output: Contribution to journalArticle

Abstract

Our immune system, fine-tuned by a long evolution, has a near-infinite capacity to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either related or unrelated to the oncogenic process, the adaptive immune system has the potential to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, probably the most significant breakthrough, is a development of the last few years. Reaching its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.

Original languageEnglish
Pages (from-to)69-82
Number of pages14
JournalActa Biologica Szegediensis
Volume59
Publication statusPublished - 2015

Fingerprint

immunotherapy
Immunotherapy
Tumors
neoplasms
Immune system
Immune System Phenomena
Neoplasms
Arsenals
immune response
recombinant antibodies
Neoplasm Antigens
Pathogens
Mutant Proteins
T-Cell Antigen Receptor
mutants
therapeutics
receptors
Immune System
cells
Proteins

Keywords

  • Antibody therapy
  • CTL
  • Dendritic cells
  • Immunotherapy
  • NK cells
  • Tumor immunology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Current approaches of tumor immunotherapy. / Buzás, Krisztina; Kiss, A.; Vízler, C.

In: Acta Biologica Szegediensis, Vol. 59, 2015, p. 69-82.

Research output: Contribution to journalArticle

@article{74e4d664beb94f7384d26ced09d6c7ff,
title = "Current approaches of tumor immunotherapy",
abstract = "Our immune system, fine-tuned by a long evolution, has a near-infinite capacity to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either related or unrelated to the oncogenic process, the adaptive immune system has the potential to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, probably the most significant breakthrough, is a development of the last few years. Reaching its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.",
keywords = "Antibody therapy, CTL, Dendritic cells, Immunotherapy, NK cells, Tumor immunology",
author = "Krisztina Buz{\'a}s and A. Kiss and C. V{\'i}zler",
year = "2015",
language = "English",
volume = "59",
pages = "69--82",
journal = "Acta Biologica Szegediensis",
issn = "1588-385X",
publisher = "University of Szeged",

}

TY - JOUR

T1 - Current approaches of tumor immunotherapy

AU - Buzás, Krisztina

AU - Kiss, A.

AU - Vízler, C.

PY - 2015

Y1 - 2015

N2 - Our immune system, fine-tuned by a long evolution, has a near-infinite capacity to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either related or unrelated to the oncogenic process, the adaptive immune system has the potential to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, probably the most significant breakthrough, is a development of the last few years. Reaching its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.

AB - Our immune system, fine-tuned by a long evolution, has a near-infinite capacity to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either related or unrelated to the oncogenic process, the adaptive immune system has the potential to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, probably the most significant breakthrough, is a development of the last few years. Reaching its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.

KW - Antibody therapy

KW - CTL

KW - Dendritic cells

KW - Immunotherapy

KW - NK cells

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84952933726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952933726&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84952933726

VL - 59

SP - 69

EP - 82

JO - Acta Biologica Szegediensis

JF - Acta Biologica Szegediensis

SN - 1588-385X

ER -